Odyssey Therapeutics (ODTX) Reports OD-001 POC, Raises $464M

This summary was generated by AI from the company's SEC filing and may contain errors — always verify against the primary source on SEC.gov.

The short version

Odyssey Therapeutics reported positive clinical proof-of-concept data for OD-001, its oral RIPK2 inhibitor, in a Phase 2a trial for moderate to severe ulcerative colitis, with 27% of patients reaching clinical remission and 61% achieving clinical response. The company closed an IPO and concurrent private placement generating $314.8 million in gross proceeds, bringing its pro-forma cash position to $464.4 million, which it expects to fund operations into the second half of 2028.

Odyssey Therapeutics, a clinical-stage drug developer focused on autoimmune and inflammatory diseases, announced its first-quarter 2026 financial results and highlighted clinical progress in its portfolio.

Positive trial results for lead candidate

The company reported positive clinical proof-of-concept data for OD-001, a small-molecule drug designed to inhibit a protein called RIPK2 and given as an oral medication. In a Phase 2a trial for moderate to severe ulcerative colitis, 49 patients completed 12 weeks of treatment. The drug was well tolerated at both doses tested, and 27% of patients achieved clinical remission (a state where the disease is controlled) while 61% achieved clinical response (improvement in symptoms).

Odyssey plans to advance OD-001 by starting two additional trials in the second half of 2026: a larger Phase 2b monotherapy trial and a Phase 2a combination trial pairing OD-001 with vedolizumab, an existing ulcerative colitis treatment. Topline results from both trials are expected in the second half of 2027.

IPO and cash raise

On May 8, 2026, Odyssey began trading on the Nasdaq under the ticker ODTX. The company closed an initial public offering (IPO—a process where a private company becomes publicly traded) alongside a concurrent private placement, raising $314.8 million in gross proceeds. The IPO consisted of 15.5 million shares of common stock and the private placement of 1.39 million shares, all priced at $18 per share. Underwriters also exercised an option to purchase an additional 600,000 shares at the same price.

Including the $314.8 million in net proceeds from these offerings and $175.7 million in cash and marketable securities already on the company's balance sheet as of March 31, 2026, Odyssey has a pro-forma cash position of $464.4 million. The company expects this to fund operations into the second half of 2028.

Financial overview

For the first quarter ended March 31, 2026, research and development expenses totaled $32.3 million, down from $38.8 million in the same quarter of 2025, primarily due to a one-time non-cash charge recorded in the prior year. General and administrative expenses were $7.4 million, compared to $8.0 million a year prior. The company reported a net loss of $38.3 million for the first quarter, essentially flat compared to a net loss of $38.4 million in the prior-year quarter.

Broader pipeline progress

Odyssey also highlighted progress on OD-002, a small-molecule inhibitor of a protein transporter called SLC15A4. The company expects to complete regulatory studies and file a clinical trial application (a regulatory request to begin human testing) in the second half of 2026, with the potential to start a Phase 1/2a trial in the first half of 2027.

Why it matters

For a clinical-stage biotech, delivering positive proof-of-concept data in a Phase 2a trial is a key milestone that de-risks the lead program and supports the therapeutic approach; combined with a successful IPO that provides 18+ months of runway, Odyssey has demonstrated investor confidence and secured capital to advance OD-001 into larger, late-stage trials. The Phase 2b and combination-therapy trials planned for late 2026 will be closely watched to confirm whether the early signal holds in a larger patient population and in combination with standard care—outcomes that could materially affect the company's value and prospects.

Frequently asked

What did Odyssey's Phase 2a trial show for OD-001?

In a 12-week Phase 2a trial for moderate to severe ulcerative colitis, 49 patients treated with OD-001 showed that 27% achieved clinical remission and 61% achieved clinical response. The drug was well tolerated at both doses tested.

How much money did Odyssey raise in its IPO?

Odyssey raised $314.8 million in gross proceeds from its IPO and concurrent private placement, with shares priced at $18 each. Including existing cash and securities, the company has a pro-forma cash position of $464.4 million.

When did Odyssey start trading as a public company?

Odyssey began trading on the Nasdaq Capital Market under the ticker symbol ODTX on May 8, 2026.

What are the next steps for OD-001?

Odyssey plans to initiate a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab in the second half of 2026, with topline results expected in the second half of 2027.

What the filing reported

2.02 Results of Operations & Financial Condition

9.01 Financial Statements & Exhibits